CD274 and non-small cell lung carcinoma: Following the landmark phase III trial Checkmate-017 comparing nivolumab to docetaxel, the Food and Drug Administration (FDA) approved nivolumab as the first anti-PD-1 agent for NSCLC with PDL-1 ≥ 1% in 2016.